Pfizer: The August Rally Is a Dividend and a Cheap Multiple, Not a Growth Story

Pfizer reported a net loss for the second quarter of 2026 — and the stock rose about 7% after the report. It had already climbed roughly 12% from the start of the year and was trading in the high $20s, a sharp turn for a name that spent the last three years sliding on the back of collapsing COVID sales. On its face, the quarter looks like a contradiction: a company that lost money, behaving like a winner.

The contradiction is the point. Pfizer's "healthy" August is real, but it is being carried by two unglamorous things — a roughly 6% dividend yield and a cheap price — not by the growth story the company keeps promising. The quarter's operating results matter, and they are worth understanding, but they explain the rally less than the cash-flow math does. Here is what is actually supporting the stock, and the single number that decides whether the health holds.

A Real Beat, Mostly the Same Story

The second-quarter results that sent the stock up were genuinely good. Revenue came in at $15.03 billion, up about 2.6% from a year earlier and above what analysts expected. The adjusted profit — the figure that strips out one-time accounting charges and is the one the market prices — was 77 cents a share, beating the 68 cents analysts had penciled in. Pfizer has now beaten its adjusted-profit estimate in ten straight quarters, and topped its revenue target in nine of the last ten.

Strip away the noise and the growth is steady, not spectacular. The core, non-COVID business grew 5% operationally — a like-for-like measure the company uses to remove currency and pricing noise — and beat its own internal target by about $1.5 billion. The engine behind it is one big drug: the blood thinner Eliquis grew 19% globally and 25% in the United States, where lower rebates and favorable channel mix lifted the number. Products Pfizer has bought — from the Seagen, Metsera, and Biohaven deals — grew 18% to $3.2 billion.

Against that, the old giant is gone. The COVID franchise that once dominated Pfizer has largely rolled off: Paxlovid sales fell 95% to $21 million, and the vaccine fell 34%. Management in fact cut its full-year COVID forecast. That is why the "beat" is mostly a story of the core holding the line while the one-time windfalls disappeared — and it is why the full-year revenue target was nudged up by $500 million, to a midpoint of about $61.5 billion, while the profit target was left unchanged.

The Write-Down the Beat Hides

Here is the part the "earnings beat" headline erases. On a standard accounting basis, Pfizer did not earn 77 cents a share in the quarter; it lost 4 cents. The difference was a $4.3 billion charge that wrote down two of its own drugs.

Most of it — $3.8 billion — was sigvotatug vedotin, a cancer drug from Pfizer's Seagen acquisition. It failed its final trial: it did not show a statistically significant survival advantage over the standard treatment in second-line lung cancer. The other slice, $525 million, went to Oxbryta, a sickle-cell drug Pfizer pulled in the United States after talks with the FDA. A write-down like this does not cost cash today, but it is the company telling you, in numbers, that an asset it paid for will not deliver what it was supposed to.

The tell is what happened next. To rebuild its cancer pipeline, Pfizer signed a $10.5 billion deal with the Chinese biotech Innovent Biologics to co-develop 12 mostly early-stage cancer drugs, paying $650 million up front. The strategy — buy growth when your own pipeline disappoints — is familiar. But the details matter: these are early-stage assets that will take years and more money to prove, and the deal already cost Pfizer a slice of third-quarter profit. For now, the oncology "renaissance" is a narrative the market is giving credit for before it has produced a single result.

Cheap, Generously Paid, and Cash-Hungry

So why does a company with a failed drug and a 6% dividend get rewarded? Because the price has done a lot of the work. Pfizer trades at about 13.5 times forward earnings — well below what its big-pharma peers command on trailing results, with Johnson & Johnson in the low 30s and Eli Lilly near 40. Its trailing multiple only looks richer than that because this quarter's one-time charge depressed past profit, so the forward number is the truer picture. And it pays a 6.2% dividend, roughly triple the yield of its large competitors, on a payout it has kept growing for 14 straight years.

That combination — a cheap price plus a real, growing dividend — is what a patient investor can actually own. But the yield is only as good as the cash behind it, and that is where the picture tightens. Pfizer's free cash flow over the past year was about $11 billion, and it is down roughly 12% from the year before. The dividend, at about $1.72 a share a year, works out to close to $10 billion across its roughly 5.7 billion shares. In other words, the payout already claims most of the cash the business produces — with about $115 billion of debt on the balance sheet behind it.

This is why the cost program is not a footnote. Pfizer has committed to roughly $9.7 billion of net savings through 2029. That program is the mechanism that turns a "cheap stock with a big dividend" from a value trap into a defensible position: the savings are what grows the cash available to keep the dividend safe. If the savings land, the cheap multiple and the 6% yield start to look almost too good to ignore. If they do not, the yield is the trap.

The Honest Read

The August rally is legitimate, but it is a valuation-and-income rally, not a growth rally. The business quality is mixed: the core is growing modestly, the one franchise that carries the thesis (Eliquis) faces a coming generic wall, the oncology platform just broke and is being rebuilt with imported early-stage assets, and free cash flow is flat to declining. The stock quality is better than the business quality right now, because the multiple is cheap and the dividend is generous — but only as long as the cash holds.

That makes it a reasonable value-and-yield position to respect, and too early to buy as a growth revival. The next two to four quarters will settle it. Watch whether the $9.7 billion of savings actually shows up and stops free cash flow from sliding; whether Eliquis holds its pricing as generic rivals approach, and whether the aging Vyndaqel can defend its price ahead of its 2028 loss of exclusivity; and whether any of the 12 Innovent assets produce real data. If the cash stabilizes, you are being paid a 6% yield at a cheap multiple while the company works on its problems. If the cash keeps eroding or the prices slip, the "healthy" August was the yield — and the yield is what is at risk.